Logo

Lynx Signs, Renews Contracts for MPSS Gene Expression Service

May 13, 2004

This story has been updated from a previous version.

 

NEW YORK, May 13 (GenomeWeb News) - Lynx Therapeutics has signed three new contracts and renewed two others for its Massively Parallel Signature Sequencing gene expression analysis service, the company said today.

 

Under a new contract with the National Cancer Institute, Lynx will apply MPSS to identify chromosome reconfigurations in cancer. In addition, under a new agreement with the National Center for Toxicogenomics of the National Institute of Environmental and Health Sciences, the company will characterize gene expression in liver and blood samples from rats treated with various doses of acetaminophen.

 

Also, under a new agreement with the Berkeley Drosophila Genome Project and scientists from the Howard Hughes Medical Institute, Lynx will analyze gene expression in different tissues and developmental stages of Drosophila.

 

Lynx renewed an existing contract with the Ludwig Institute for Cancer Research, to continue work that had started in 2002 with NCI to characterize gene expression in cancer. The company also extended an existing agreement with the National Institute of Aging to study stem cell gene expression.

Breaking News
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.